Aptissen S.A. is a Swiss company specialized in the development and commercialization of biopolymer-based medical devices. Aptissen’s founders have developed for the past 25 years the best quality injectable products which meet both patients and doctors expectations.

The company was founded in 2013 as a spin-off of ANTEIS, and is based in Geneva area, Switzerland. It today distributes its products through a worldwide international distributors’ network among more than 50 countries including Europe, South America, Canada, Middle East and Asia for instance.

Aptissen’s team revolutionized the viscosupplement market with Synolis VA and his patented formulation which combines Hyaluronic Acid and Sorbitol. Synolis VA provides rapid mobility recovery, fast long lasting pain relief associated with excellent safety: www.synolis.com


Aptissen considers that the future of treatments for the synovial joints requires effective treatments administered in a single session, providing an improvement in mobility and a fast pain relief, as well as the regeneration of cartilage.


By 2018, half-million of joints were treated with Aptissen’s products. We place the patient benefit at the center of our mission to develop innovative injectable solutions based on hyaluronic acid that can be combined with other molecules. We plan to bring a clinically proven global approach, including oral or topical forms.


Aptissen launched Synolis VA, a intra-articular injection product for osteoarthritis, the first Visco-Antalgic on the market, with a unique combination of Hyaluronic Acid and high concentration of Sorbitol.
Synolis VA’s viscoelastic properties (patented formulation) are similar to the young and healthy synovial fluid, resulting in rapid mobility recovery, fast and long-lasting pain relief associated with excellent safety.


The Aptissen team, originating from Anteis, owns knowledge and experience of both products and markets.
Joints treated
Operating since
Markets served